Kornimate/medical-research-clean huggingface dataset:
ovarian tissue freezing for fertility preservation

Conditions: Malignancy; Fertility

Summary: the purpose of this study is to offer an alternative method to women who wish to preserve the possibility of fertility, as well as to learn more about the ability of human eggs to survive and function after long term storage in frozen ovaries (ovarian tissue cryopreservation). the study will seek to preserve ovarian tissue and reproductive potential for patients whose medical or surgical treatment may harm ovaries or remove ovarian tissue.

women who have not yet undergone this procedure, and who present to the fertility consultants desiring fertility preservation, will be offered participation in the study. subjects will undergo an initial visit which will include a blood draw, ultrasound, and any additional tests or exams that are medically indicated for the subject's diagnosis in preparation for surgery. subjects will then undergo an oophorectomy surgery (removal of one or both ovaries). following removal, subject's ovarian tissue will be cryopreserved (frozen) and stored for possible future use. we also plan to collect subjects medical history information to enter into a research database. subjects will be followed until they decide to use their tissue for fertility purposes. we will also retrospectively enroll women who have already undergone this procedure by contacting them by mail and offering participation in our ovarian tissue cryopreservation database.

Eligibility criteria:
inclusion criteria: * woman between the age of 18-41 years who will undergo surgery, chemotherapy, drug treatment and/or radiation for the treatment or prevention of a medical condition or malignancy expected to result in permanent and complete loss of subsequent ovarian function or have a medical condition or malignancy that requires removal of all or part of one or both ovaries. * patients may have newly diagnosed or recurrent disease. those who were not enrolled at the time of initial diagnosis are eligible if they have not received therapy that is viewed as likely to result in complete and permanent loss of ovarian function. * for patients undergoing elective removal of an ovary for fertility preservation only, have two ovaries. * patients who already have stored cryopreserved ovarian tissue in a frozen state prior to undergoing cancer treatments (surgery, chemotherapy or radiation) will be eligible for enrollment with informed consent. * signed an approved informed consent and authorization permitting the release of personal health information. the patient and/or the patient's legally authorized guardian must acknowledge in writing that consent for specimen collection has been obtained, in accordance with institutional policies approved by the u.s. department of health and human services. exclusion criteria: * women with psychological, psychiatric, or other conditions which prevent giving fully informed consent. * women whose underlying medical condition significantly increases their risk of complications from anesthesia and surgery.

Keywords: ovarian tissue cryopreservation
evaluation of a patient portal intervention to address diabetes care gaps

Conditions: Diabetes Mellitus

Summary: the purpose of this study is to evaluate the usability of a novel patient portal intervention designed to: (a) notify patients when selected, clinically meaningful, evidence-based diabetes monitoring \& preventative care (e.g., annual diabetes eye exam) become due and (b) allow patients to initiate orders for the care. in addition, the investigators will assess pre-post change on secondary psychosocial outcomes (e.g., self-efficacy).

up to 60 adult patients with type 1 or 2 diabetes mellitus will be enrolled and given access to a new feature within the patient portal at vanderbilt university medical center. the new feature will be available via the patient portal native app (i.e., my health at vanderbilt (mhav) app) for mobile devices (smartphone or tablet). the new feature will allow patients to: (1) receive notifications when the patient is due for certain types of diabetes monitoring and preventative care and (2) initiate an order for the care. study participants will complete questionnaires electronically via email at three time points: baseline (t0), immediately after first use of the intervention (t1), and three-month follow-up (t2) to as assess study outcomes including usability and pre-post change in secondary psychosocial outcomes.

Eligibility criteria:
inclusion criteria: * established patient at participating primary care clinic * type 1 or 2 diabetes mellitus * able to speak and read in english * age 18 to 75 years old * mobile device (smartphone or tablet) with internet access * active mhav account and willing and able to use the mhav native app on a mobile device * due (based on evidence-based guidelines) for any of the following: hemoglobin a1c, urine microalbumin, diabetes eye exam, and/or pneumococcal vaccination. exclusion criteria: * known cognitive deficits or functional impairment preventing the use of a mobile device * pregnant or planning to become pregnant during the study period * severe difficulty seeing * severe difficulty hearing * medical condition that make it hard for people to understand what they are saying

Keywords: diabetes mellitus medical informatics preventative care
studying tumor samples from young patients with neuroblastoma

Conditions: Neuroblastoma

Summary: this research study is looking at tumor samples from young patients with neuroblastoma. studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer

study subtype: ancillary/correlative observational study model: cohort time perspective: retrospective biospecimen retention: samples with dna biospecimen description: tissue study population description: patients previously enrolled on clinical trial cog-anbl00b1 sampling method: non-probability sample primary objective: i. to comprehensively identify and characterize the spectrum and frequency of mutations in alk across all neuroblastoma disease subsets using methodologies that will be resource neutral to the children's oncology group neuroblastoma nucleic acids bank. secondary objectives: i. to formulate genetic screening recommendations for newly diagnosed patients with or without a family history of neuroblastoma. ii. to identify the functionally relevant alk mutations that can be pharmacologically inhibited. iii. to test for the prognostic capability of alk alterations. iv. to determine the clinical significance of alk mutations and/or genomic rearrangements by combining alk mutation, amplification, and translocation data overall and within each neuroblastoma risk group and correlating this information with clinical phenotype (i.e., age, international neuroblastoma staging system stage, and international neuroblastoma pathology classification); genetic factors (i.e., ploidy, mycn status); and patient outcome. outline: tumor dna samples are examined by mutation analysis for germline and somatic mutations in the alk tyrosine kinase domain. samples are analyzed by whole genome amplification using polymerase chain reaction and then sequenced for dna alterations in the entire alk coding sequence. samples are also examined for single nucleotide polymorphisms (snps) by polymorphism analysis. exploratory multivariable analysis is performed to test for the prognostic ability of alk mutations in the presence of other known prognostic variables (i.e., age, international neuroblastoma staging system stage, mycn status, international neuroblastoma pathology classification, and diploidy). a subset of tumor dna samples from high-risk patients will be resequenced for dna alterations to determine whether or not additional regions in alk, outside of the tyrosine kinase domain, are prone to mutations and should be sequenced in a larger panel.

Eligibility criteria:
inclusion criteria: * tumor dna samples available from pediatric patients with newly diagnosed neuroblastoma previously enrolled on clinical trial cog-anbl00b1
ventriculostomies in sah: icp open or not?

Conditions: Subarachnoid Hemorrhage

Summary: the purpose of this study is explore how cerebrospinal fluid (csf) drainage impacts outcomes for patients diagnosed with subarachnoid hemorrhage (sah). this is a non-randomized observational study of two physician-prescribed approaches to managing intracranial pressure monitoring and csf drainage for sah patients. the study will enroll only those patients who have intracranial pressure (icp) monitoring in situ. because this is an observational study, there are no physical risks to the patient, the only risk is loss of confidentiality.

there are no interventions specific to this observational study. the nurses and physicians who care for subjects in the study are already competent in the care and management of patients with subarachnoid hemorrhage (sah) and intracranial pressure (icp) monitoring as a requirement of their current employment at duke university. patients with confirmed diagnosis of subarachnoid hemorrhage requiring icp and csf management will be admitted to the 16 bed neurocritical care unit (nccu) at duke hospital. after admission procedures and a baseline neurologic assessment are complete, the charge nurse or nccu fellow will notify an investigator of subjects meeting inclusion criteria. the investigator or research coordinator for this project will complete a review preparatory to research (rpr) to ensure no exclusion criteria are present and once subject appropriateness has been confirmed patients and their families will be introduced to the investigator for the purpose of obtaining informed consent. the subject's legally authorized representative (lar) will be informed of the study's purpose, risks and benefits, and the rights of research subjects. data will be collected that reflects the duration of the patient's hospitalization at duke university through chart abstraction. the study period will be defined as admission to discharge. the attending physician has, and will continue to, determine the appropriateness of the duration of icp monitoring, nccu discharge criteria and hospital discharge criteria. chart abstraction will be completed daily to obtain the icp values and csf volumes during that period of time for which the patient has a ventriculostomy.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of subarachnoid hemorrhage * age 18 years or older * ventriculostomy in situ exclusion criteria: * prisoners * glasgow coma score = 3

Keywords: cerebrospinal fluid ventriculostomy subarachnoid hemorrhage vasospasm human subjects
correlation and predictive research of metal elements in radiation-induced oral mucositis

Conditions: Head and Neck Tumors; Metal; Copper; Radiotherapy-Induced Oral Mucositis

Summary: radiotherapy is the main treatment method for head and neck tumors. however, almost all patients with head and neck tumors will develop acute inflammatory reactions such as radiotherapy-induced oral mucositis (riom) after receiving radiotherapy, resulting in a decline in the quality of life of patients, hindering the smooth implementation of the treatment plan, reducing the therapeutic effect, and increasing the economic burden of patients. however, the current treatment strategies for riom focus on symptomatic treatment and have little impact on the course, severity and related complications of mucositis. therefore, exploring effective strategies, predicting the incidence and severity of riom in patients, and providing prevention and treatment are the clinical bottlenecks and cutting-edge issues that urgently need to be solved in the current clinical practice of radiotherapy for head and neck tumors. previous studies have shown that the steady-state of metallic elements may be closely related to the occurrence and development of riom. therefore, we plan to conduct a prospective, single-center, observational study to further explore the correlation between metal elements and severe riom, analyze its predictive efficacy, and observe the dynamic changes of metal elements in radiotherapy.


Eligibility criteria:
inclusion criteria: 1）sign the informed consent form; 2) confirmed by pathological biopsy as nasopharyngeal carcinoma or head and neck tumors; 3) have indications for radiotherapy and voluntarily accept radiotherapy; 4) ecog ps: 0/1; 5) age: 18-75 years old; 6) laboratory tests confirm good organ function. exclusion criteria: 1. there are contraindications for radiotherapy; 2. combined with other tumors; 3. pathological sections could not be obtained; 4. the patient has any serious concurrent diseases that may pose unacceptable risks or have a negative impact on trial compliance. for instance, unstable heart diseases requiring treatment, chronic hepatitis, kidney diseases with poor conditions, uncontrolled diabetes (fasting blood glucose greater than 1.5 × uln), and mental disorders; 5. the researcher judged that it was not suitable to participate in this study.
effect of ketamine addition to lidocaine in rhinoplasty

Conditions: Nose Deformities, Acquired

Summary: the purpose of this study is to determine whether subanesthetic ketamine addition to lidocaine decreases postoperative pain scores in infiltration anesthesia during rhinoplasty.

in rhinoplasty operations local infiltration anesthesia uses for surgery insight and patient comfort. the investigators designed this study to prolonged the time of infiltration block and preventive analgesia. so, before operation, study drugs will infiltrate to the submucosa of intranasal cavity. then, surgeon and patient satisfaction, postoperative analgesic demand, postoperative pain scores and side effects will determine.

Eligibility criteria:
inclusion criteria: * patients scheduled for elective rhinoplasty operation under general anesthesia * patients with asa (american society of anesthesiology) class i * patients between 18-50 years old exclusion criteria: * age \ 50 * asa \> ii * preexisting neurological or psychiatric illness * systemic diseases (diabetes mellitus, hypertension, coronary heart disease...) * having a history of chronic pain and receiving chronic analgesia therapy * having a history of drug abuse
prostate artery embolization as a treatment for benign prostatic hyperplasia in men with prostates larger than 90 grams

Conditions: Prostatic Hyperplasia

Summary: the purpose of the study is to evaluate improvement in symptoms related to benign prostatic hyperplasia (bph) in men treated with prostate artery embolization (pae) using embosphere microspheres.

the study will evaluate improvement in symptoms associated with benign prostatic hyperplasia (bph) in men with prostates larger than 90 grams treated with prostate artery embolization (pae). symptoms will be assessed utilizing the international prostate symptom score (ipss) to evaluate change from baseline at 12 months post pae.

Eligibility criteria:
inclusion criteria: * patient has provided signed informed consent * patient is aged greater than or equal to 40 and less than or equal to 89 years of age * patient has a prostate size between 90g and 200g, as determined by mri * patient has experienced lower urinary tract symptoms (luts) for at least 6 months prior to study enrollment * patient has an ipss score of at least 13 at baseline * patient is either: refractory to medical treatment, contraindicated to medical treatment, or refuses medical treatment * patient either: refuses surgical treatment or is contraindicated for surgical treatment * patient meets one of the following criteria: baseline psa \ /= 4 ng/ml and a negative prostate biopsy (minimum 12 core biopsy) within the prior 12 months exclusion criteria: * history of prostate, bladder, or rectal cancer * history of transurethral resection of the prostate (turp), open prostate surgery, or radiofrequency or microwave therapies * history of open bladder, rectosigmoid colon, or other pelvic surgery * patient is unwilling to discontinue alpha blockers 1 month after study treatment * patient is unwilling to discontinue 5-alph reductase inhibitors 1 month after study treatment * neurogenic bladder or other neurologic disorder impacting bladder function such as parkinson's disease, multiple sclerosis, cerebral vascular accident or diabetes * any other confounding bladder or urethral pathology, including urethral stricture, bladder neck contracture, or bladder atonia * active prostatitis or urinary tract infection * cystolithiasis within the past 3 months * serum creatinine \> 1.7mg/dl * inability to discontinue oral anticoagulant 2-5 days prior to study treatment * coagulation disturbances not normalized by medical treatment * iodinated contrast allergy that, in the opinion of the investigator, cannot be adequately premedicated * gelatin allergy * known severe peripheral vascular disease or major iliac arterial occlusive disease * interest in future fertility * clinically significant cardiac arrhythmia or other cardiac disease (including congestive heart failure), uncontrolled diabetes mellitus, clinically significant respiratory disease, or known immunosuppression * other condition that the investigator believes puts the patient at risk for a complication during the procedure

Keywords: bph prostatic hyperplasia enlarged prostate benign prostatic hypertrophy
dexamethasone versus methylprednisolone for the treatment of active inflammatory bowel disease

Conditions: Inflammatory Bowel Disease (IBD)

Summary: the aim of this therapeutic trial is to compare the response of subjects with active ibd to daily intravenous dexamethasone versus the response to daily intravenous methylprednisolone.


Eligibility criteria:
inclusion criteria: * parental informed consent * subjects 6 to 19 years of age with confirmed diagnosis of ibd (crohn's disease, ulcerative colitis or indeterminate colitis), who on admission to the hospital have a pcdai\>15 or a clinical-activity index for the evaluation of patients with ulcerative colitis of \>10. * infectious causes (viruses, bacteria, parasites) have been ruled out. exclusion criteria: * subjects in which the administration of corticosteroids would be contraindicated such as systemic or enteric infections diagnosed by stool analysis including culture, clostridium difficile toxin assay, rotavirus or adenovirus 40/41 antigens. * subjects with enterostomy or colostomy * subjects with one or more of the following conditions: unstable vital signs, acute abdomen, toxic megacolon, intestinal obstruction, intestinal perforation

Keywords: inflammatory bowel disease (ibd)
refusal to participate in a randomized trial involving pregnancy and childbirth: factors associated with refusal and reasons for refusal and acceptance

Conditions: Pregnancy Related

Summary: the main objective is to assess whether there are factors associated with women's refusal to participate in a randomized clinical trial involving pregnancy and childbirth in france. the secondary objective is to qualitatively evaluate the reasons for acceptance and refusal to participate.

1. determine the acceptance/refusal rate among all women identified, eligible and offered rct. 2. comparison of demographic characteristics between the two groups * group 1: women accepting to participate in rct * group 2: women refusing to participate in rct 3. assessment of motivations for acceptance (based on questionnaire given to women who agree to participate) 4. evaluation of reasons for refusal to participate - obstacles (based on the questionnaire given to women who refuse to participate).

Eligibility criteria:
inclusion criteria: the study will be offered to all women who have been offered to participate in a randomized trial relating to their pregnancy and/or childbirth in participating services. exclusion criteria: none

Keywords: refusal clinical trial factors reasons pregnancy pre-eclampsia
chemotherapy treatment for children with intraocular germ-line retinoblastoma

Conditions: Retinoblastoma; Retinal Neoplasms

Summary: retinoblastoma is an unusual cancer of early childhood involving tumor is both eyes or, in certain circumstances, one eye only. this condition is the result of an abnormal gene which makes both retinas (the back of the eye) vulnerable to develop multiple tumors. growths in the eye impair vision temporarily or permanently. these tumors are malignant, which means that they can grow within the eye, spread outside of the eye, and be fatal if untreated. standard therapy for bilateral retinoblastoma includes removal of one eye if vision cannot be save and radiation treatment of either eye in which vision might be saved. radiation controls tumor growth in the majority of cases. another standard method is cryotherapy (freezing a tumor to kill it). chemotherapy (medicines used to kill tumor cells) has been used in the past for tumor in or outside the eye, but is not standard. hyperthermia, increasing the temperature of a tumor to kill it, is widely performed, and can be done to a retinoblastoma tumor by a laser; this method is not standard. the problem with removal of an eye is that any hope of vision is lost. the problems with radiation include incomplete control of tumor, injury to the eye or surrounding tissue with decreased growth, and that (due to the abnormal retinoblastoma gene) children are very susceptible to develop other tumors, especially in the tissue which was given radiation. the doctors at children's memorial hospital are using a newer form of treatment, including laser hyperthermia, chemotherapy and cryotherapy to decrease retinoblastoma tumors. some may be controlled indefinitely, reducing the number of eyes that need radiation or removal. objectives 1. to find out how well chemotherapy plus cryotherapy and laser hyperthermia work on retinoblastoma tumors. 2. to find out whether vision can be saved and tumors controlled without radiation or removal of the eye.


Eligibility criteria:
eligibility criteria: * initial clinical diagnosis of retinoblastoma, with bilateral tumors, or unilateral tumor with hope for salvage of vision and multiple primary tumors, or positive family history for retinoblastoma, or age \< 12 months * no prior antitumor therapy (except enucleation of one eye) * at least one tumor exceeds 6 mm in diameter * no evidence of dissemination outside the globe * signed irb-approved informed consent * patient/family available for follow-up
suspension system on impingement syndrome

Conditions: Impingement Syndrome

Summary: to investigate the effect of shoulder exercise using a selected suspension system exercise program on pain, disability, functional performance and proprioception in patients with subacromial impingement syndrome.

two groups were assigned to this study, the first one received four conventional exercises that designed for shoulder impingement syndrome, the second group received the same four conventional exercises plus four selected suspension system exercises. the sessions were conducted three times per week fir four weeks.

Eligibility criteria:
inclusion criteria: 1. fifty-eight subjects with sis (more than three months). 2. their age ranges from 20-45 years old 3. level of pain (at least 2/10 on vas) 4. body mass index (bmi) between 18-25 5. subjects must show positive results in at least two of the following tests: neer's impingement test, hawkins-kennedy test, supraspinatus (empty can) test, apprehension and relocation test. exclusion criteria: the subjects will be excluded if they had: 1. received physiotherapy at last 3 months. 2. received corticosteroids injection in subacromial space at last 3 months. 3. received anti-inflammatory medications. 4. have a fracture or dislocation in shoulder, neck and thoracic regions. 5. have an acute rotator cuff tear. 6. have tumor or malignancy in shoulder region. 7. have neurologic problems in shoulder, neck and thoracic regions. 8. have cooperation difficulties due to cognitive disorders.